R Street Institute: Scheduling 7-OH as Schedule I Would Block Research and Push Users to the Black Market

Why it matters

A leading free-market think tank argues that placing 7-OH on Schedule I before adequate science is in would deter future therapeutic research and could force dependent users into dangerous illicit markets — the same dynamic seen during the prescription opioid crackdown.

The big picture

Schedule I is the most restrictive federal drug classification, requiring researchers to navigate significant bureaucratic and funding barriers to study classified substances. Critics of rapid scheduling point to cannabis and CBD as examples of substances trapped on Schedule I for decades despite evidence of medical utility. The rescheduling of Epidiolex from Schedule I to V in 2018 is among the very rare exceptions.

Key findings

• Congress is considering H.R. 8000 to place 7-OH on Schedule I without completing the standard eight-factor scientific analysis required by the Controlled Substances Act
• Current safety data on 7-OH is based on small case series relative to the likely hundreds of thousands of annual users
• Schedule I classification makes research costly and difficult, potentially blocking discovery of therapeutic applications in pain and opioid use disorder
• Cutting off access could trigger withdrawal crises and push dependent users to illicit alternatives — echoing the trajectory seen after opioid prescribing clampdowns
• Rescheduling a substance after placement on Schedule I is historically rare and arduous

What they say

R Street Institute analyst Stacey McKenna wrote: "This rush to place 7-OH on the most restrictive level of the drug schedule before the science is clear deters that research and could have other unintended consequences."

Bottom line

Placing 7-OH on Schedule I now — without completing a full scientific review — could make the substance permanently harder to study and inadvertently harm people dependent on it.